Showing 3911-3920 of 4063 results for "".
- Merck's Pembrolizumab Demonstrates Positive Results in Phase III Study for Advanced Melanomahttps://practicaldermatology.com/news/mercks-pembrolizumab-demonstrates-positive-results-in-phase-iii-study-for-advanced-melanoma/2458959/Merck announced results from the randomized, pivotal Phase III study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, pembrolizumab was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
- Alma Lasers Introduces Harmony XL Pro Multi-Application Platformhttps://practicaldermatology.com/news/alma-lasers-introduces-harmony-xl-pro-multi-application-platform/2458987/Alma Lasers introduced the Harmony XL Pro™ platform to its product portfolio. The platform will be presented at the American Academy of Dermatology Meeting in San Francisco, CA from March 21 - 23 at Booth 2428. The Harmony XL Pro platform consists of multiple modules offering powerf
- Merz Announces Availability of Radiesse® (+) with Integral 0.3% Lidocainehttps://practicaldermatology.com/news/merz-announces-availability-of-radiesse-with-integral-03-lidocaine/2458992/Radiesse® (+) with integral 0.3% Lidocaine (Radiesse® Plus) from Merz North America, US affiliate of the global Merz Pharma Group, has received FDA approval and is now available to US physicians. Radiesse® (+) provides the immediate lift of wrinkles an
- Promius Pharma, LLC to Market, Distribute Trianex 0.05%https://practicaldermatology.com/news/promius-pharma-llc-to-market-distribute-trianex-005/2458997/Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of
- Can-Fite Receives Notice of Allowance in US for Psoriasis Patenthttps://practicaldermatology.com/news/can-fite-receives-notice-of-allowance-in-us-for-psoriasis-patent/2459005/Can-Fite BioPharma Ltd. received a Notice of Allowance from the US Patent and Trademark Office for CF101 in the treatment of psoriasis. The patent, which is expected to be issued in the next few weeks, is titled, "Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist (IB-M
- XTRAC Offering Rebate for Excimer Laser Treatmentshttps://practicaldermatology.com/news/xtrac-offers-coupon-for-vitiligo-treatments/2459029/PhotoMedex is offering a limited-time rebate for patients treated with the XTRAC Excimer Laser from January 1 through March 31, 2015. The rebate is worth up to $100 per treatment and can be used to offset the costs of insurance deduc
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-thre
- Alcohol Intake Not Linked to Early BCChttps://practicaldermatology.com/news/alcohol-intake-not-linked-to-early-bcc/2459036/Despite some trends suggesting that high alcohol use and high UV exposure may be associated with risk for early onset BCC in women, there is no statistically significant association between lifetime alcohol intake and early-onset BCC overall or in women only, new data from the
- Galderma Laboratories Launches First OTC Acne Regimen, Benzac® Acne Solutionshttps://practicaldermatology.com/news/galderma-laboratories-launches-first-otc-acne-regimen-benzac-acne-solutions/2459041/Galderma Laboratories, L.P., maker of Cetaphil®, is launching Benzac® Acne Solutions, its first-ever, over-the-counter (OTC) acne regimen. Benzac treats stubborn acne and prevents new breakouts from forming with salicylic acid, while pharmaceutical grade East Indian Sandalwood Oil calms a
- Brodalumab Outperforms Ustekinumab in Head-to-Head Trialhttps://practicaldermatology.com/news/20141112-brodalumab_outperforms_ustekinumab_in_head-to-head_trial/2459070/New findings from the Phase III AMAGINE-3 trial suggest that the investigational IL-17 inhibitor brodalumab (Amgen/AstraZeneca) may be superior to ustekinumab in treating patients with moderate to severe psoriasis. In the study, investigators evaluated more than 1,800 patients who were randomized to